Abstracts

Smoking and Obesity May Partially Explain the Inflammation and Morbidity Association

Background: As in the general population, increased central obesity and smoking are correlated with higher levels of soluble inflammatory markers in HIV+ virally suppressed patients. We previously reported that high levels of IL-6, sTNFR-1 and 2 and D-dimer were associated with an occurrence of a non-AIDS event. Understanding the pathophysiology of inflammation in HIV and…

Infectious and Noninfectious Multimorbidity Among HIV Clinic Clients in the African Cohort Study

Background: The frequency and complexity of multimorbidity in the increasingly treated African HIV epidemic is not comprehensively described. Methods: The African Cohort Study (AFRICOS) prospectively enrolls adult HIV clinic clients and uninfected adults at 10 PEPFAR supported facilities in Kayunga, Uganda; South Rift Valley and Kisumu West, Kenya; Mbeya, Tanzania and Abuja, Nigeria. We evaluated…

Bone Metabolism and Tenofovir: Evidence of Direct Effect on Calcium-Sensing Receptor

Background: Bone health impairment is a common finding in HIV-infected patients on antiretroviral treatment. Bone mineral derangement is the result of bone metabolism alterations, associated to some antiretroviral agents. We previously reported high serum parathyroid hormone (PTH) concentration in patients on HAART containing tenofovir disoproxil fumarate (TDF). Hyperparathyroidism in these patients was not always sustained…

Bone Turnover on DRV/r + Either RAL or TDF/FTC as First-Line ART: NEAT 001 / ANRS 143

Background: Darunavir/ritonavir (DRV/r) + raltegravir (RAL) was associated with significantly less bone mineral density (BMD) loss over 96 weeks than DRV/r + tenofovir/emtricitabine (TDF/FTC) in first-line treatment of HIV-infected patients. Changes in bone and inflammatory biomarkers could partially explain differences in BMD loss. Methods: NEAT001/ANRS143 is a randomised 1:1, open-label trial comparing DRV/r + RAL…

Tenofovir Replacement in Patients With Osteoporosis Increased Sclerostin Levels

Background: Background: Tenofovir is one of the antiretroviral drugs involved in accelerated bone mineral density (BMD) loss. Methods: Methods: We recently published changes in 54 virologically suppressed patients during a tenofovir-containing regimen and criteria for osteopenia/osteoporosis who were randomized to switch from tenofovir to abacavir (n=26) or to continue with tenofovir (n=28). Forty-eight weeks after…

Relationship Between Phosphate Reabsorption, Age, Tenofovir and Bone Mineral Density

Background: The functional capacity of renal tubules to reabsorb phosphate declines with age. The extent to which this is affected by tenofovir (TDF) exposure and its effects on bone are unknown. We investigated the association between phosphate reabsorption, age, TDF exposure and bone mineral density (BMD). Methods: Male HIV-positive patients taking part in a prospective…

Long-Term Changes in Bone Mineral Density and Insulin Resistance on Statins in HIV

Background: We previously demonstrated increased hip bone mineral density (BMD) and worsening in insulin resistance after 48 weeks of rosuvastatin in HIV-infected adults on antiretroviral therapy (ART). Here, we present the final 96 week results. Methods: The Stopping Atherosclerosis and Treating Unhealthy bone with RosuvastatiN in HIV (SATURN-HIV) trial is a randomized, double-blind, placebo-controlled trial…